Your letter head
Give this to patients to have with them when
They see a physician or dentist
The bearer of this letter is a patient in a methadone maintenance treatment program.
Methadone patients frequently need treatment for other medical, surgical, and dental conditions.
At times the health professional is not familiar with addictive disease and the various forms of
treatment, including maintenance pharmacotherapy using methadone or LAAM. The reaction to
being informed about the addictive disease/methadone treatment often includes fear, anger,
prejudice, disgust, and other negative subjective responses, none of which contribute to the
objective delivery of quality health care. Many patients are very reluctant to provide information
to the other health professional about their addiction and treatment with methadone or LAAM
because of previous unpleasant experiences. The most common reaction is based on fear and
disgust which is inversely proportional to the professional's level of familiarity with addiction
medicine and patients with addictive diseases. The purpose of this brief letter is to touch on the
most common problems encountered and to offer any assistance I might be able to provide.
It is widely accepted that addictions are diseases and that their treatment is a legitimate part of
medical practice. Addictive disease can be characterized as a chronic, relapsing, progressive,
probably incurable, and often fatal (if untreated) disorder. The principle diagnostic features are
obsession, compulsion, and continued use despite adverse consequences (loss of control).
Methadone has been used in the treatment of opioid dependence for over 30 years. It has been
found to be both effective and safe in long term administration. An adequate individualized daily
dose of methadone eliminates drug craving, prevents the onset of withdrawal, blocks (through
opiate cross-tolerance) the effects typical of other opiates, such as heroin or morphine. Efficacy
of treatment is based on elimination of or reductions in illicit/inappropriate drug use, elimination
or marked reduction in illegal activities, improved employment, pro-social behavior and
improved general health. Such treatment has been shown to be effective in reduction of the
spread of HIV and other infections. Dramatic reductions in mortality rates are seen in
methadone maintained patients in comparison to untreated addicted populations.
The methadone maintained patient develops complete tolerance to the analgesic, sedative,
and euphoric effects of the maintenance dose of methadone. Tolerance does not develop to
the effects of reducing drug hunger and preventing the onset of withdrawal syndrome.
Methadone has a half-life in excess of 24 hours which makes single daily dosing possible.
Methadone has a relatively flat blood plasma level curve that will prevent the onset of abstinence
syndrome for over 24 hours without causing any sedation, euphoria or impairment of function.
Along with discrimination, and related to the same stigma, the failure to provide adequate
treatment of pain methadone maintained patients is a common and very serious problem..
Since the patient is fully tolerant to the maintenance dose of methadone No analgesia is
realized from the regular daily dose of methadone. Relief of pain depends on maintaining
the established tolerance level with methadone and then providing additional analgesia. Studies
have shown that exposure to adequate doses of narcotics for the relief of acute severe pain does
not compromise treatment of the addiction.
Non-narcotic analgesics should be used when pain is not severe. In the event of more severe
pain the use of opioid agonist drugs is quite appropriate. The dose of opioid agonist drugs, such
as morphine, is usually increased to compensate for the opioid cross tolerance established by
the methadone. Also, the duration of analgesia may be less than usual. Doses must be
individually titrated to ensure adequate analgesia. Best results are obtained with a scheduled
dosing as opposed to PRN. Morphine may be required q 2-3 hours at whatever dose that
There is no justification for subjecting a maintenance patient to unnecessary pain and suffering
because of their disease or its treatment. Adequate treatment of pain will ensure a more
pleasant hospital stay as well as enhance healing and recuperation.
Opioid partial agonist and agonist/antagonist drugs such as Buprenex, Talwin, Stadol,
and Nubaine should never be used in the methadone tolerant individual. Severe opiate
withdrawal syndrome can be precipitated by drugs of this type.
Both propoxyphene and meperidine are known to produce CNS excitatory metabolites. Due to
the cross tolerance the higher doses required to achieve analgesia can increase the risk of
seizures. For this reason propoxyphene and meperidine should be avoided in the maintenance
The administration of opioid agonist drugs should be closely supervised in terms of quantities
and duration. Prescribing for self-administration by the patient should be carefully monitored. If
it is necessary to prescribe for self administration, caution should be exercised in the amounts
prescribed and refills carefully supervised.
Similar precautions are indicated in the prescribing of sedative/hypnotic and CNS stimulant
drugs. The abuse potential of ALL benzodiazepines is quite high.
At times the attending physician is tempted to treat the opioid dependence itself. This is usually
attempted by tapering the methadone dose to zero. If successful, the graded reduction may
result in a reduction or elimination of the physical dependence but has no effect on the disease
itself. Even after the methadone is discontinued significant signs and symptoms of abstinence
may persist for several weeks and even months. The relapse rate associated with detoxification
alone approaches 100%. A relapse to street/illicit drugs increases risk of overdose, hepatitis,
AIDS, and a host of other biomedical, psycho-social, legal, and other complications.
Under some circumstances some form of intervention can be accomplished during a hospital
stay for other conditions when desired by the patient and in consultation with the methadone
program physician. Such a process should involve experienced addiction professionals with a
strong emphasis on continuity of care upon discharge.
If you have any questions or concerns about our mutual patient in relation to methadone or drug
dependency please call me. I would be delighted to hear from you.
Your name and special instructions